CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4 Planned sale Chief Financial Officer sold 40,000 shares at an average $30.19 ($1,207,742)
- 4 Planned sale Co-Chief Executive Officer sold 100,000 shares at an average $29.84 ($2,983,838)
- 4 Planned sale Co-Chief Executive Officer sold 100,000 shares at an average $29.84 ($2,983,678)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Director sold 30,000 shares at $27.70 ($830,904)
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Medical Officer sold 10,028 shares at an average $32.40 ($324,868)
- 4 Open-market sale Chief Financial Officer sold 10,810 shares at an average $32.36 ($349,821)
- 4 Open-market sale Chief Legal Officer sold 9,536 shares at an average $32.46 ($309,506)
- 4 Open-market sale Co-Chief Executive Officer sold 30,464 shares at an average $32.18 ($980,263)
- 4 Open-market sale Co-Chief Executive Officer sold 30,464 shares at an average $32.19 ($980,504)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
Page 1 of 23 · 446 filings